Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00416
|
|||||
| Drug Name |
Cytarabine
|
|||||
| Synonyms |
(beta-D-Arabinofuranosyl)cytosine; 1-.beta.-D-arabinofuranosyl-cytosine; 1-Arabinofuranosylcytosine; 1-beta-D-Arabinofaranosylcytosine; 1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone; 1-beta-D-Arabinofuranosylcytosine; 1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside; 1-beta-D-Arabinosylcytosine; 1beta-Arabinofuranasylcytosine; 1beta-D-Arabinofuranosylcytosine; 1beta-D-Arabinosylcytosine; 2(1H)-Pyrimidinone, 4-amino-1-D-arabinofuranosyl-[CAS]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine; 4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone; 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; 4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one; AR3; Alexan; Ara-C; Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine; Ara-Cytidine; AraC; Arabinocytidine; Arabinofuranosylcytosine; Arabinosyl Cytosine; Arabinosylcytosine; Arabitin; Aracytidine; Aracytin; Aracytine; Arafcyt; BTB15125; Beta-Ara C; Beta-Arabinosylcytosine; Beta-D-Arabinosylcytosine; Beta-cytosine arabinoside; CHX 3311; CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9); Citarabina; Citarabina [INN-Spanish]; Cytarabin; Cytarabina; Cytarabine (JP15/USP/INN); Cytarabine [USAN:INN:BAN:JAN]; Cytarabine liposome injection; Cytarabinoside; Cytarabinum; Cytarabinum [INN-Latin]; Cytarbel; Cytonal; Cytosar; Cytosar-U; Cytosar-U (TN); Cytosine 1-beta-D-arabinofuranoside; Cytosine arabinofuranoside; Cytosine arabinose; Cytosine arabinoside; Cytosine arabinoside (VAN); Cytosine beta-D-arabinofuranoside; Cytosine beta-D-arabinofuranoside hydrochloride; Cytosine beta-D-arabinoside; Cytosine, beta-D-arabinoside; Cytosine-1-beta-D-arabinofuranoside; Cytosine-beta-D-arabinofuranoside; Cytosine-beta-arabinoside; Cytosinearabinoside; DepoCyte; Depocyt; Depocyt (TN); Depocyt (liposomal); Erpalfa; Intrathecal (injected into the spinal fluid) DepoCyt; Intrathecal cytarabine (also known as ara-C); Iretin; Spongocytidine; Tarabine; U 19920A; U-19,920; U-19920; Udicil
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Acute lymphoblastic leukemia [ICD11: 2B33.0] | Approved | [1] | |||
| Chronic myelogenous leukemia [ICD11: 2A20.0] | Approved | [1] | ||||
| Acute myeloid leukemia [ICD11: 2A60] | Approved | [1] | ||||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C9H13N3O5
|
|||||
| Canonical SMILES |
C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O
|
|||||
| InChI |
InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1
|
|||||
| InChIKey |
UHDGCWIWMRVCDJ-CCXZUQQUSA-N
|
|||||
| CAS Number |
CAS 147-94-4
|
|||||
| Pharmaceutical Properties | Molecular Weight | 243.22 | Topological Polar Surface Area | 129 | ||
| Heavy Atom Count | 17 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
-2.1
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103210760
, 103986361
, 104253284
, 104311532
, 11528303
, 11533128
, 117529237
, 118048876
, 12146044
, 124648720
, 124757405
, 124799562
, 14774115
, 15196510
, 24858315
, 24892435
, 26527898
, 26719755
, 29215144
, 29225249
, 3260118
, 46386862
, 46505879
, 47193873
, 47573376
, 48415837
, 49831046
, 50105698
, 53787662
, 56310997
, 56311029
, 56312269
, 56312943
, 56313129
, 56313612
, 5877
, 598052
, 76890970
, 7847236
, 7885952
, 7979015
, 8153933
, 829245
, 83110442
, 87558791
, 90341066
, 92308449
, 92309014
, 93166529
, 93167157
|
|||||
| ChEBI ID |
ChEBI:28680
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | CNT1 | Transporter Info | Concentrative nucleoside transporter 1 | Substrate | [2] | |
| ENT1 | Transporter Info | Equilibrative nucleoside transporter 1 | Substrate | [2] | ||
| ENT2 | Transporter Info | Equilibrative nucleoside transporter 2 | Substrate | [2] | ||
| OCT-1 | Transporter Info | Organic cation transporter 1 | Substrate | [3] | ||
| OCTN1 | Transporter Info | Organic cation/carnitine transporter 1 | Substrate | [4] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [5] | ||
| References | ||||||
| 1 | Cytarabine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia. Oncotarget. 2016 Aug 2;7(31):49786-49799. | |||||
| 3 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
| 4 | OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. Cancer Res. 2017 Apr 15;77(8):2102-2111. | |||||
| 5 | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.